Profile
Matthew J.
Pietras worked as the Chief Operating & Financial Officer at StageZero Life Sciences Ltd.
in 2021-2022.
Prior to that, he was the Treasurer & Controller at Viela Bio, Inc. from 2017-2019.
He also worked as the Vice President-Finance at CiVi Biopharma, Inc. His education includes an MBA from The Johns Hopkins University and an undergraduate degree from The Pennsylvania State University.
Former positions of Matthew J. Pietras
Companies | Position | End |
---|---|---|
STAGEZERO LIFE SCIENCES LTD. | Director of Finance/CFO | 2022-05-25 |
VIELA BIO, INC. | Comptroller/Controller/Auditor | 2018-12-31 |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Director of Finance/CFO | - |
Training of Matthew J. Pietras
The Johns Hopkins University | Masters Business Admin |
The Pennsylvania State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
STAGEZERO LIFE SCIENCES LTD. | Health Technology |
Private companies | 2 |
---|---|
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Health Technology |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
- Stock Market
- Insiders
- Matthew J. Pietras